Wedbush Expects Higher Earnings for Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Investment analysts at Wedbush boosted their Q1 2025 EPS estimates for shares of Fennec Pharmaceuticals in a research report issued to clients and investors on Monday, March 10th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.10) per share for the quarter, up from their prior forecast of ($0.14). Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at $0.33 EPS, Q4 2025 earnings at $0.42 EPS and FY2026 earnings at $2.20 EPS.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Tuesday. Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Trading Up 1.6 %

Shares of NASDAQ FENC opened at $6.50 on Thursday. The stock has a market cap of $179.15 million, a price-to-earnings ratio of -64.99 and a beta of 0.36. The company has a 50 day simple moving average of $6.39 and a two-hundred day simple moving average of $5.63. Fennec Pharmaceuticals has a 12 month low of $3.96 and a 12 month high of $11.49.

Hedge Funds Weigh In On Fennec Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Advantage Alpha Capital Partners LP acquired a new stake in Fennec Pharmaceuticals during the 3rd quarter valued at $264,000. State Street Corp increased its stake in Fennec Pharmaceuticals by 2.2% during the 3rd quarter. State Street Corp now owns 328,259 shares of the company’s stock valued at $1,641,000 after buying an additional 7,053 shares during the period. Barclays PLC increased its stake in Fennec Pharmaceuticals by 274.3% during the 3rd quarter. Barclays PLC now owns 31,319 shares of the company’s stock valued at $157,000 after buying an additional 22,951 shares during the period. Franklin Resources Inc. grew its stake in shares of Fennec Pharmaceuticals by 18.7% in the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock worth $74,000 after purchasing an additional 2,330 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Fennec Pharmaceuticals by 12.9% in the fourth quarter. Rhumbline Advisers now owns 34,299 shares of the company’s stock worth $217,000 after acquiring an additional 3,911 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Insiders Place Their Bets

In related news, Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $6.08, for a total transaction of $60,800.00. Following the transaction, the director now owns 83,863 shares of the company’s stock, valued at approximately $509,887.04. This represents a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 31,186 shares of company stock worth $203,389. 10.98% of the stock is owned by company insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.